home / stock / achl / achl news

ACHL News and Press, Achilles Therapeutics plc From 05/05/21

Stock Information
Company Name: Achilles Therapeutics plc
Stock Symbol: ACHL
Market: NASDAQ
Website: achillestx.com
Menu
ACHL ACHL Quote ACHL Short ACHL News ACHL Articles ACHL Message Board
Get ACHL Alerts

News, Short Squeeze, Breakout and More Instantly...
ACHL - Achilles Therapeutics to present at the BofA Securities 2021 Virtual Healthcare Conference

LONDON, May 05, 2021 (GLOBE NEWSWIRE) -- Achilles Therapeutics plc (NASDAQ: ACHL), a clinical-stage biopharmaceutical company developing precision T cell therapies to treat solid tumors, today announced that Iraj Ali, Chief Executive Officer, will participate in a fireside chat at the BofA ...
ACHL - Achilles Therapeutics Appoints Julie O'Neill to Board of Directors and Markwin Velders, Ph.D. joins Scientific Advisory Board

LONDON, United Kingdom, May 03, 2021 (GLOBE NEWSWIRE) -- Achilles Therapeutics plc (NASDAQ: ACHL), a clinical-stage biopharmaceutical company developing precision T cell therapies to treat solid tumors, today announces the appointment of Julie O’Neill as a Non-Executive Director to t...

ACHL - HCA Healthcare downgraded despite strong Q1 results, LHC Group becomes a new catalyst call; and more in today's analyst action

The anticipated impact on healthcare in a post-pandemic setup has led to contrasting views on two different healthcare providers: HCA Healthcare and LHC Group. Furthermore, several initiations are also included in today’s analyst action.HCA Healthcare downgraded at CitiCiti analysts Ra...

ACHL - Achilles Therapeutics Demonstrates cNeT Product Characterization and Post-Infusion Tracking in a Patient Case Study at the American Association for Cancer Research (AACR) 2021 Annual Meeting

LONDON, April 10, 2021 (GLOBE NEWSWIRE) -- Achilles Therapeutics plc (NASDAQ: ACHL), a clinical-stage biopharmaceutical company developing precision T cell therapies to treat solid tumors, today presented a patient case study from the Company’s ongoing Phase I/IIa THETIS trial in met...
ACHL - Achilles Therapeutics Announces Closing of $175.5 million Initial Public Offering

LONDON, April 06, 2021 (GLOBE NEWSWIRE) -- Achilles Therapeutics plc (NASDAQ: ACHL), a clinical-stage biopharmaceutical company developing precision T cell therapies to treat solid tumors, today announced the closing of its previously announced initial public offering in the United States o...

Previous 10 Next 10